Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement

Dow Jones

08/18

By Connor Hart

Adaptive Biotechnologies said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026.

Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products.

As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology.

Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement.

Shares of Adaptive fall 1.7% in premarket trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

August 18, 2025 08:53 ET (12:53 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2560190018"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560190018\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560190018?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560190018","market":"sg","top_or_hot":-1,"title":"Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026. \n</p>\n<p>\n  Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products. \n</p>\n<p>\n  As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology. \n</p>\n<p>\n  Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement. \n</p>\n<p>\n  Shares of Adaptive fall 1.7% in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 08:53 ET (12:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies, Genentech to Terminate Strategic Agreement\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-08-18 20:53</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026. \n</p>\n<p>\n  Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products. \n</p>\n<p>\n  As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology. \n</p>\n<p>\n  Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement. \n</p>\n<p>\n  Shares of Adaptive fall 1.7% in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 08:53 ET (12:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2560190018","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560190018","pubTimestamp":1755521580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Adaptive Biotechnologies said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026.Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products.As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology.Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement.Shares of Adaptive fall 1.7% in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BK4007":"制药","RHHBY":"罗氏控股","ADPT":"Adaptive Biotechnologies Corp","03165":"华夏欧优股对冲"},"translate_title":"Adaptive Biotechnologies与基因泰克终止战略协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"ADPT":0.9,"RHHBY":0.9},"content_text":"By Connor Hart \n\n\n \n\n\nAdaptive Biotechnologies said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026. \n\n\n  Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products. \n\n\n  As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology. \n\n\n  Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement. \n\n\n  Shares of Adaptive fall 1.7% in premarket trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 08:53 ET (12:53 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}